RedBrick AI
AI NativeRapid & Collaborative Medical Data Annotation
Est 2020|Raised $5.1M
Rapid & Collaborative Medical Data Annotation
Published Jul 14, 2026
The vendor publishes regular product updates that include changes to consensus workflows, model integration options, analytics, project lifecycle management, and segmentation tooling. Active development indicates evolving functionality, which can alter workflows over time and should be evaluated during a proof of concept.
Areas where competitors may have advantages include broader modality coverage, larger public review footprints, and longer-established enterprise ecosystems.
Public, impartial review coverage for the vendor’s medical-annotation product is limited. Major review platforms did not surface verified, product-specific reviews for RedBrick AI (medical annotation) during this research. Some platform search results reference different organizations with similar or identical names, which increases the difficulty of collecting independent customer feedback.
Public social channels and forums contain limited or mixed-quality mentions. Brand-name collisions with other entities named “Redbrick” complicate automated or manual searches and can result in false positives when gathering feedback. Some LinkedIn posts describe efficiency gains in labeling operations; these are informative but generally marketing-adjacent and should be validated.
No credible, directly attributable very low-rated reviews for the vendor’s medical-annotation product were found on mainstream review platforms in the sources reviewed. The vendor’s troubleshooting documentation lists common operational issues (such as login or cache problems), which may reflect routine SaaS support items rather than systemic product failures.
The vendor has published performance claims such as reductions in annotation time, citing relative improvements and speedups versus manual annotation. The methodologies for these claims (baselines, dataset characteristics, annotator expertise) are not published, so such claims should be validated through pilots using an organization’s own data and annotators.
Press releases from third parties describe partnerships that reference compliance and efficiency benefits. Press releases and partner announcements are promotional in nature but provide signals that the vendor’s technology is being embedded in some service-provider workflows.
The product likely fits organizations with sufficient labeling operations to justify a specialized tool — typically small-to-mid-size companies up through larger teams. Very small teams with only a handful of people may find the platform heavier than necessary unless they manage substantial DICOM volumes and require quality-control workflows.
Decision-makers: Heads of ML/AI, VPs of Engineering, Heads of Data/Labeling Operations, Clinical AI Directors, and Security/IT stakeholders for hospital deployments. End users include radiologists, trained annotators, QA reviewers, and project managers.
Get a comprehensive analysis of RedBrick AI including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →Organizations that do not require DICOM-native radiology workflows: for natural images, video, or text-focused projects, general-purpose labeling platforms or open-source tools may be more cost-effective.
Organizations that require extensive third-party review validation before purchasing: robust product review coverage was not identified for the vendor’s medical-annotation product in mainstream review platforms; procurement processes that rely heavily on public review footprints may prefer vendors with larger independent review presences.
Organizations that require ISO 27001 (or similar) as a procurement gate: public evidence of ISO certification was not found in the reviewed materials.
Organizations with highly elastic labeling headcount that prefer usage-based billing to seat-based billing: a seat-based model with proration rules and no mid-period credits for removals may be a poor fit for bursty labeling workloads.
Organizations that require a fully offline, entirely on-premises application without a browser dependency: the vendor delivers a web application and while it supports customer-hosted storage options, the product is delivered as a SaaS web app.
The following differentiators are supported by vendor documentation and public materials. These are statements of vendor positioning and should be validated in technical evaluation and procurement conversations.
Areas where competitors may have advantages include broader modality coverage, larger public review footprints, and longer-established enterprise ecosystems.
Vendor-published case studies and quotes state favorable outcomes. For example, a vendor case study attributed to Annalise.ai states that RedBrick AI is an important part of their AI development workflow. Vendor materials also include claims that the vendor’s segmentation tooling is unique among cloud software.
Interpretation: These vendor-published materials indicate favorable experiences for some advanced radiology AI teams, particularly around volumetric segmentation and workflow support, but they are curated marketing materials and should not be treated as representative of typical customer experience without independent validation.
Vendor materials report a large-scale chest X-ray labeling project involving hundreds of thousands of chest X-rays labeled multiple times, totaling millions of label data points, and state that the customer migrated from a general-purpose labeling vendor to RedBrick AI for radiology-specific tooling. These scale figures and statements are presented in vendor-authored case studies and have not been independently audited. Outcomes achieved by an advanced, well-resourced team may not generalize to smaller organizations without equivalent annotation operations.
RedBrick AI is a software-as-a-service platform for medical imaging (radiology) data annotation and dataset operations. It provides a browser-based DICOM-first viewer with 2D/3D annotation tools (notably segmentation), project and workforce management, and quality-control workflows to produce labeled datasets intended for training and validating medical imaging AI models.
Vendor-emphasized product themes:
Primary target buyers and users:
Positioning is radiology-first (DICOM-focused), which contrasts with general-purpose labeling platforms that support broader computer-vision and generative-AI labeling use cases. The vendor also emphasizes features for clinical validation workflows used in regulatory studies rather than only model-training labeling.